|
Avidity Biosciences Inc (NASDAQ: RNA) |
|
Avidity Biosciences Inc
RNA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Avidity Biosciences Inc 's sales fell
by -28.27 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 1971
Major Pharmaceutical Preparations industry recorded
growth of revenues by 4.5 %
Avidity Biosciences Inc net loss increased from $-60 millions, to $-116 millions in first quarter of 2025,
• More on RNA's Growth
|
|
Avidity Biosciences Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 54.53 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 404.62.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.2.
• More on RNA's Valuation
|
|
|
|
|
Avidity Biosciences Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 54.53 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 404.62.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.2.
Avidity Biosciences Inc Price to Book Ratio is at 2.94 lower than Industry Avg. of 33.28. and higher than S&P 500 Avg. of 0.01
• More on RNA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com